Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: A prospective randomised controlled trial

Lancet

Volumn 354, Issue 9177, 1999, Pages 456-460

  Davies, L ^a   Angus, R M ^a   Calverley, P M A ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; PREDNISOLONE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; OXYGEN THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; SYMPTOM;

EID: 0033533144     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)11326-0     Document Type: Article

References (23)

1. BT S guidelines for the management of chronic obstructive pulmonary disease. The COPD guidelines group of the standard of care committee of the BT S. Thorax 1997; 52 (suppl 5): S1-28.
2. Siafakas NM, Vermeine P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1398-420.
3. Callahan CM, Cittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease: a meta-analysis. Ann Intern Med 1991; 114: 216-23.
4. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155: 542-48.
5. Decramer M, de Bock V, Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 1958-64.
6. Emerman CL, Connors AF, Lukens TW, May ME, Effron D. A randomised controlled trial of methylprednisolone in the emergency treatment of acute exacerbations of chronic obstructive pulmonary disease. Chest 1989; 95: 563-67.
7. Bullard MJ, Liaw SJ, Tsai YH, Min HP. Early corticosteroid use in acute exacerbations of chronic airflow limitation. Am J Emerg Med 1996; 14: 139-43.
8. Albert RK, Martin TR, Lewis SW. Controlled trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med 1980; 92: 753-58.
9. Thompson WH, Nielson CP, Carvalho P, Cheran NB, Crowley JJ. Controlled trial of oral prednisolone in outpatients with acute chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med 1996; 154: 407-12.
10. Neiwoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999; 340: 1941-47.
11. Angus RM, Keith RKC, Kat JW, Manie RD, Patel KR. A prospective audit of the inpatient management of patients with chronic airflow limitation. Thorax 1995; 50: 445P.
12. Gibson PG, Wlodarczyk JH, Wilson AJ, Sprogis A. Severe exacerbation of chronic obstructive airways disease: health resource use in general practice and hospital. J Qual Clin Pract 1998; 18: 125-33.
13. Poole PJ, Bagg B, Brodie SM, Black PN. Characteristics of patients admitted to hospital with chronic obstructive pulmonary disease. N Z Med J 1997; 110: 272-75.
14. American Thoracic Society 1987. Standardisation of spirometry 1987 update. Am Rev Respir Dis 1987; 136: 1285-98.
15. Quanjer PH. Standardised lung function testing: official statement of the European Resiratory Society. Eur Respir J 1993; 6 (suppl 16): 5-40.
16. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure for chronic airflow limitation: the St George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-27.
17. Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436-42.
18. Murray CJL, Lopez AD. Mortality by cause for eight major regions of the world: Global Burden of Disease Study. Lancet 1997; 349: 1269-76.
19. Moayyedi P, Congleton J, Page RL, Pearson SB, Muers MH. Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. Thorax 1995; 50: 834-37.
20. Gravil JH, Al-Rawas OA, Cotton MM, Flanigan U, Irwin A, Stevenson RD. Home treatment of exacerbations of chronic obstructive pulmonary disease by an acute respiratory assessment service. Lancet 1998; 351: 1853-55.
21. Osman IM, Godden DJ, Friend JA, Legge JS, Douglas JG. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 1997; 52: 67-71.
22. Maestrelli P, Saetta M, Di Stefano A, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Crit Care Med 1994; 150: 1646-52.
23. Confalonieri M, Mainardi E, Della Porta R, et al. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998; 53: 583-85.